Erbitux Drug Interactions

In combination with platinum-based chemotherapy, the frequency of severe leukopenia or severe neutropenia may be increased, and thus may lead to a higher rate of infectious complications eg, febrile neutropenia, pneumonia and sepsis compared to platinum-based chemotherapy alone (see Precautions).
In combination with infusional 5-fluorouracil, the frequency of cardiac ischaemia including myocardial infarction and congestive heart failure as well as the frequency of hand-foot syndrome (palmar-plantar erythrodysaesthesia) were increased compared to that with infusional 5-fluorouracil.
A formal interaction study showed that the pharmacokinetic characteristics of cetuximab remain unaltered after co-administration of a single dose of irinotecan (350 mg/m² body surface area).
Similarly, the pharmacokinetics of irinotecan were unchanged when cetuximab was co-administered.
No other formal interaction studies with cetuximab have been performed in humans.
Incompatibilities: Erbitux must not be mixed with other medicinal products except those mentioned in Cautions For Usage.